Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year, driven by approximately $11 million in net sales of TONMYA, its recently approved treatment for fibromyalgia. The company reported 12,592 total prescriptions for TONMYA during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%. This commercial momentum underscores the market's acceptance of TONMYA as the first new fibromyalgia treatment in over 15 years.
The strong sales performance is supported by broad payer coverage. TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on January 1, 2027, further enhancing patient access and potential revenue growth.
Beyond its commercial achievements, Tonix is advancing a robust clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder (MDD). This study is designed to evaluate the efficacy and safety of TNX-102 SL in patients with MDD, a condition with significant unmet medical need. Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These initiatives highlight the company's commitment to addressing critical therapeutic areas.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, combined with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides a solid foundation for the company to execute its strategic objectives.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. In addition to TONMYA, the company's CNS commercial infrastructure supports its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is also maximizing the science behind TONMYA by evaluating its potential in Phase 2 clinical trials for MDD and acute stress disorder. The company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In immunology, Tonix is advancing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The impressive revenue growth and pipeline progress position Tonix as a key player in the biotech sector. The success of TONMYA is particularly noteworthy, as it addresses a long-standing need in fibromyalgia treatment. The expansion of payer coverage and the potential approval of new indications could drive sustained growth. Moreover, the advancement of TNX-102 SL and TNX-4800 into later-stage trials demonstrates the company's ability to innovate and diversify its portfolio. With a strong cash position, Tonix is well-equipped to navigate the complexities of drug development and commercialization.
Investors and industry observers will be watching closely as Tonix continues to execute on its commercial and clinical strategies. The company's progress not only enhances its own prospects but also contributes to the broader landscape of CNS and immunology therapeutics. As TONMYA gains traction and the pipeline matures, Tonix Pharmaceuticals is poised for continued success in the coming years.
